ClinicalTrials.Veeva

Menu

A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies

T

Tianjin Medical University

Status

Active, not recruiting

Conditions

Esophageal Cancer
Gastric (Stomach) Cancer

Treatments

Other: Nutritional Supplement

Study type

Interventional

Funder types

Other

Identifiers

NCT06997302
TJMUCH-GI-ST01

Details and patient eligibility

About

An increasing body of evidence suggests that nutritional status is a key factor in determining the quality of life of cancer patients. The sensitivity of cancer patients to anti-tumor treatments, the occurrence of side effects, and their quality of life are closely related to their nutritional status. Data show that about 50% of cancer patients experience a weight loss of more than 10% at the time of diagnosis and treatment, and once patients enter a cachexia state, the weight loss becomes difficult to reverse. Therefore, the extent to which nutritional interventions can impact clinical outcomes in these patients needs to be answered through clinical research. Currently, there are few studies using randomized controlled trials (RCTs) to explore how nutritional interventions can improve patients' quality of life, particularly in terms of prolonging survival. A recent RCT in a smaller sample population found that long-term, intensive, individualized nutritional counseling and support not only improved malnutrition in cancer patients, reduced treatment complications, and enhanced quality of life but also significantly extended survival time.

This study is a prospective, randomized controlled clinical trial aimed at investigating the effect of full-scale intelligent nutrition management in gastrointestinal malignancy patients (esophageal cancer, gastric cancer) undergoing chemotherapy. The study attempts to confirm that full-scale intelligent nutrition management can benefit these patients by maintaining or improving their nutritional status, and that the clinical effectiveness of intelligent nutrition management is comparable to that of professional nutritionists. This research will also provide clinical evidence for the intelligent and standardized nutritional treatment of cancer patients during the chemotherapy period.

Enrollment

150 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥ 18 years;
  2. Voluntarily agree to participate and sign the informed consent form;
  3. Diagnosed with gastrointestinal malignancy (esophageal cancer, gastric cancer) and planned to undergo chemotherapy;
  4. Physical activity is acceptable, and capable of undergoing body composition analysis.

Exclusion criteria

  1. Uncontrolled or severe heart, liver, lung, and kidney diseases;
  2. History of stroke, epilepsy, or primary brain cancer, or patients with brain metastases from cancer;
  3. Pregnant individuals;
  4. Individuals allergic to milk, whey protein, etc.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

150 participants in 3 patient groups

Control group.
No Intervention group
Description:
In the Control group, necessary nutritional support or dietary guidance were provided by clinical physicians following standard clinical procedures.
Study group 1
Experimental group
Description:
In Research Group 1, nutritional status was assessed using a clinical nutrition analyzer, with interventions tailored to the system-generated "Nutritional Diagnosis Report" and recommendations.
Treatment:
Other: Nutritional Supplement
Study group 2
Experimental group
Description:
Patients in Research Group 2 underwent evaluation by a multidisciplinary team comprising clinical physicians and dietitians, who collaboratively designed and delivered nutritional support.
Treatment:
Other: Nutritional Supplement

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems